⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292558 | 0.85 | NPC1 (0.40) | — | |
| SCHEMBL17943853 | 0.84 | NPC1 (0.42) | — | |
| SCHEMBL9020584 | 0.84 | NPC1 (0.42) | — | |
| SCHEMBL9020965 | 0.84 | NPC1 (0.42) | — | |
| Hydrochloric Acid SCHEMBL31094672 | 0.82 | NPC1 (0.41) | — | |
| SCHEMBL255119 | 0.81 | — | — | |
| SCHEMBL984869 | 0.80 | — | — | |
| SCHEMBL10049904 | 0.80 | — | — | |
| SCHEMBL1764531 | 0.80 | — | — | |
| SCHEMBL1780286 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117321055-A | Modulators of STING (interferon gene stimulators) | 辉瑞公司 | 2023-12-29 | — | — | CN | disclosed |
| WO-2023217879-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| US-20230150909-A1 | PHENYLACETIC ACID DERIVATIVE, USE THEREFOR, AND PRODUCTION INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230150909-A1 | PHENYLACETIC ACID DERIVATIVE, USE THEREFOR, AND PRODUCTION INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230058729-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-02-23 | — | — | US | disclosed |
| US-11136327-B2 | Macrocycles as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3808739-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3786165-A1 | SYNTHETIC INTERMEDIATES FOR PRODUCING MACROCYCLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20200390100-A1 | SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AG (DE) | 2020-12-17 | — | — | US | disclosed |
| EP-2534154-B1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-2287162-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2287161-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-23 | — | — | EP | disclosed |
| EP-2284169-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | Otsuka Pharmaceutical Co., Limited (JP) | 2011-02-16 | — | — | EP | disclosed |
| CN-101918368-A | Method for improving the hydrolysis stability of ionic liquids | BASF SE | 2010-12-15 | — | — | CN | disclosed |
| US-20100267596-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASE SE (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2229365-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASF SE (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| WO-2009077452-A1 | METHOD FOR IMPROVING THE HYDROLYSIS STABILITY OF IONIC LIQUIDS | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009014730-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |